Trials / Completed
CompletedNCT01241214
Study of ACT-129968 in Adult Patients With Seasonal Allergic Rhinitis
A Multi-center, Double-blind, Randomized, Placebo-controlled, Active Reference, Parallel-group, Study of ACT-129968 in Adult Patients With Seasonal Allergic Rhinitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 579 (actual)
- Sponsor
- Idorsia Pharmaceuticals Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the efficacy and safety of different doses of ACT-129968 in adult patients with seasonal allergic rhinitis, due to mountain cedar pollen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ACT-129968 | ACT-129968 (Dose 1, Dose 2, or Dose 3) or matching placebo administered orally twice daily |
| DRUG | ACT-129968 | ACT-129968 (Dose 4) \& matching placebo administered orally once daily |
| DRUG | Cetirizine | Ceterizine administered once daily |
| DRUG | Placebo | Matching placebo administered twice daily. |
Timeline
- Start date
- 2010-11-01
- Primary completion
- 2011-02-01
- Completion
- 2011-02-01
- First posted
- 2010-11-16
- Last updated
- 2019-05-15
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01241214. Inclusion in this directory is not an endorsement.